Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 24 | 2026 | 1134 | 4.570 |
Why?
|
| Cardiomyopathies | 6 | 2023 | 517 | 1.920 |
Why?
|
| Biliary Atresia | 5 | 2025 | 220 | 1.740 |
Why?
|
| Acute-On-Chronic Liver Failure | 4 | 2025 | 73 | 1.620 |
Why?
|
| Liver Cirrhosis | 7 | 2024 | 909 | 1.280 |
Why?
|
| Liver Failure, Acute | 4 | 2024 | 96 | 1.160 |
Why?
|
| Bile Acids and Salts | 5 | 2023 | 259 | 1.160 |
Why?
|
| Myocardium | 3 | 2021 | 865 | 1.120 |
Why?
|
| End Stage Liver Disease | 5 | 2024 | 191 | 0.980 |
Why?
|
| Multiple Organ Failure | 3 | 2022 | 144 | 0.830 |
Why?
|
| Airway Extubation | 1 | 2024 | 70 | 0.800 |
Why?
|
| Liver | 4 | 2023 | 1804 | 0.740 |
Why?
|
| Renal Replacement Therapy | 3 | 2024 | 164 | 0.660 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 501 | 0.640 |
Why?
|
| Perioperative Care | 1 | 2021 | 217 | 0.590 |
Why?
|
| Myocardial Contraction | 2 | 2018 | 245 | 0.590 |
Why?
|
| Tracheostomy | 1 | 2021 | 213 | 0.580 |
Why?
|
| Cholic Acids | 1 | 2018 | 16 | 0.570 |
Why?
|
| Critical Care | 2 | 2021 | 688 | 0.560 |
Why?
|
| Extracorporeal Circulation | 1 | 2018 | 46 | 0.550 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2018 | 301 | 0.540 |
Why?
|
| Infant | 17 | 2026 | 13332 | 0.530 |
Why?
|
| Plasma Exchange | 1 | 2018 | 84 | 0.520 |
Why?
|
| Hemodynamics | 1 | 2021 | 809 | 0.520 |
Why?
|
| Cardiotonic Agents | 1 | 2018 | 139 | 0.520 |
Why?
|
| Cholic Acid | 3 | 2014 | 19 | 0.510 |
Why?
|
| Child | 25 | 2026 | 26220 | 0.460 |
Why?
|
| Retrospective Studies | 18 | 2026 | 17764 | 0.460 |
Why?
|
| Postoperative Complications | 3 | 2024 | 3133 | 0.400 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 90 | 0.390 |
Why?
|
| Child, Preschool | 16 | 2026 | 15018 | 0.390 |
Why?
|
| Pyridines | 2 | 2014 | 258 | 0.390 |
Why?
|
| Hospital Costs | 2 | 2024 | 181 | 0.390 |
Why?
|
| Cholestasis | 2 | 2014 | 164 | 0.370 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 193 | 0.370 |
Why?
|
| Thrombolytic Therapy | 1 | 2014 | 202 | 0.370 |
Why?
|
| Liver Failure | 2 | 2026 | 99 | 0.350 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 191 | 0.350 |
Why?
|
| Male | 27 | 2026 | 64783 | 0.350 |
Why?
|
| Waiting Lists | 2 | 2021 | 242 | 0.340 |
Why?
|
| Heart Atria | 1 | 2013 | 335 | 0.330 |
Why?
|
| Bile Duct Diseases | 1 | 2010 | 16 | 0.320 |
Why?
|
| Anticoagulants | 4 | 2022 | 602 | 0.300 |
Why?
|
| Humans | 32 | 2026 | 130980 | 0.290 |
Why?
|
| Thrombosis | 3 | 2022 | 498 | 0.280 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2010 | 164 | 0.280 |
Why?
|
| Diet, Atherogenic | 1 | 2008 | 14 | 0.280 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2011 | 360 | 0.280 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 675 | 0.270 |
Why?
|
| Adolescent | 11 | 2026 | 20817 | 0.270 |
Why?
|
| Citric Acid | 2 | 2018 | 47 | 0.270 |
Why?
|
| Hepatitis | 1 | 2008 | 57 | 0.270 |
Why?
|
| Prognosis | 4 | 2024 | 4950 | 0.270 |
Why?
|
| Blood Group Incompatibility | 2 | 2018 | 27 | 0.260 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2008 | 141 | 0.260 |
Why?
|
| ABO Blood-Group System | 2 | 2018 | 61 | 0.260 |
Why?
|
| Mice, Knockout | 5 | 2023 | 3839 | 0.250 |
Why?
|
| Risk Factors | 6 | 2024 | 11022 | 0.250 |
Why?
|
| Heart | 2 | 2011 | 667 | 0.240 |
Why?
|
| Liver Diseases | 2 | 2022 | 384 | 0.240 |
Why?
|
| Mice, Inbred C57BL | 6 | 2023 | 4716 | 0.240 |
Why?
|
| Female | 20 | 2026 | 70723 | 0.240 |
Why?
|
| Length of Stay | 3 | 2024 | 1399 | 0.240 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 735 | 0.230 |
Why?
|
| Thrombelastography | 1 | 2026 | 66 | 0.220 |
Why?
|
| Heart Failure | 1 | 2018 | 2322 | 0.220 |
Why?
|
| Nutritional Support | 1 | 2025 | 67 | 0.220 |
Why?
|
| Blood Loss, Surgical | 1 | 2026 | 169 | 0.220 |
Why?
|
| Treatment Outcome | 8 | 2022 | 12957 | 0.220 |
Why?
|
| Critical Illness | 4 | 2021 | 616 | 0.210 |
Why?
|
| Parenteral Nutrition | 1 | 2025 | 216 | 0.210 |
Why?
|
| Enteral Nutrition | 1 | 2025 | 282 | 0.200 |
Why?
|
| Ferritins | 2 | 2021 | 108 | 0.200 |
Why?
|
| Adenovirus Infections, Human | 1 | 2023 | 60 | 0.190 |
Why?
|
| Necrosis | 1 | 2022 | 195 | 0.180 |
Why?
|
| Intensive Care Units | 2 | 2018 | 518 | 0.180 |
Why?
|
| Hemodiafiltration | 1 | 2021 | 17 | 0.170 |
Why?
|
| Gastroenterology | 1 | 2024 | 223 | 0.170 |
Why?
|
| Fatty Acids | 2 | 2016 | 377 | 0.170 |
Why?
|
| Survival Rate | 2 | 2024 | 2145 | 0.170 |
Why?
|
| ADAMTS13 Protein | 1 | 2021 | 66 | 0.160 |
Why?
|
| Animals | 9 | 2023 | 34025 | 0.160 |
Why?
|
| Bacterial Infections | 1 | 2023 | 322 | 0.160 |
Why?
|
| Gastroenteritis | 1 | 2023 | 308 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 171 | 0.160 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 157 | 0.160 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 4683 | 0.150 |
Why?
|
| Bacteremia | 1 | 2023 | 427 | 0.150 |
Why?
|
| von Willebrand Factor | 1 | 2021 | 192 | 0.150 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 5246 | 0.150 |
Why?
|
| Sepsis | 1 | 2023 | 496 | 0.150 |
Why?
|
| Serum Albumin, Human | 1 | 2018 | 8 | 0.140 |
Why?
|
| Ventricular Function, Left | 2 | 2014 | 542 | 0.140 |
Why?
|
| Signal Transduction | 4 | 2018 | 4675 | 0.140 |
Why?
|
| Cause of Death | 2 | 2018 | 509 | 0.140 |
Why?
|
| Hemofiltration | 1 | 2018 | 11 | 0.140 |
Why?
|
| Cytoprotection | 1 | 2018 | 37 | 0.140 |
Why?
|
| Biliary Tract Diseases | 1 | 2018 | 33 | 0.140 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2018 | 66 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2018 | 91 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2021 | 1515 | 0.140 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 90 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1241 | 0.130 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 252 | 0.130 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8568 | 0.120 |
Why?
|
| Mice | 6 | 2023 | 18287 | 0.110 |
Why?
|
| Echocardiography | 2 | 2019 | 1137 | 0.110 |
Why?
|
| Time Factors | 3 | 2017 | 6231 | 0.110 |
Why?
|
| Tissue Donors | 1 | 2018 | 501 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 692 | 0.100 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2013 | 16 | 0.100 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2014 | 79 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2014 | 247 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2018 | 2911 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2014 | 191 | 0.090 |
Why?
|
| Catheterization | 1 | 2014 | 231 | 0.090 |
Why?
|
| Cardiovirus Infections | 1 | 2011 | 6 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 753 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2014 | 446 | 0.090 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2011 | 49 | 0.090 |
Why?
|
| Portal Vein | 2 | 2022 | 88 | 0.090 |
Why?
|
| Dicarbethoxydihydrocollidine | 1 | 2010 | 3 | 0.080 |
Why?
|
| Ventricular Remodeling | 1 | 2011 | 155 | 0.080 |
Why?
|
| Glycogen | 1 | 2010 | 50 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2010 | 45 | 0.080 |
Why?
|
| Myocarditis | 1 | 2011 | 132 | 0.080 |
Why?
|
| Recurrence | 1 | 2014 | 1481 | 0.080 |
Why?
|
| Amino Acids | 2 | 2023 | 566 | 0.080 |
Why?
|
| Gene Expression | 2 | 2013 | 1495 | 0.080 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 223 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2019 | 5100 | 0.080 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 301 | 0.070 |
Why?
|
| Fatigue | 1 | 2010 | 196 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2018 | 3417 | 0.070 |
Why?
|
| Chemokine CXCL2 | 1 | 2008 | 7 | 0.070 |
Why?
|
| Fibrosis | 1 | 2010 | 420 | 0.070 |
Why?
|
| Cholesterol, Dietary | 1 | 2008 | 48 | 0.070 |
Why?
|
| Chemokine CCL5 | 1 | 2008 | 53 | 0.070 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2008 | 55 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2008 | 112 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2011 | 972 | 0.060 |
Why?
|
| Heart Ventricles | 1 | 2011 | 771 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2008 | 276 | 0.060 |
Why?
|
| International Normalized Ratio | 1 | 2026 | 45 | 0.060 |
Why?
|
| Fatty Liver | 1 | 2008 | 222 | 0.060 |
Why?
|
| Blood Coagulation Tests | 1 | 2026 | 66 | 0.060 |
Why?
|
| Partial Thromboplastin Time | 1 | 2026 | 55 | 0.060 |
Why?
|
| Fibrinogen | 1 | 2026 | 166 | 0.060 |
Why?
|
| Blood Coagulation | 1 | 2026 | 134 | 0.060 |
Why?
|
| Organ Dysfunction Scores | 1 | 2025 | 53 | 0.060 |
Why?
|
| Asia | 1 | 2025 | 125 | 0.050 |
Why?
|
| Brain Edema | 1 | 2024 | 66 | 0.050 |
Why?
|
| Biomarkers | 1 | 2014 | 3403 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 3059 | 0.050 |
Why?
|
| India | 1 | 2024 | 243 | 0.050 |
Why?
|
| ROC Curve | 1 | 2026 | 617 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2025 | 301 | 0.050 |
Why?
|
| Receptors, Purinergic | 1 | 2023 | 13 | 0.050 |
Why?
|
| Receptors, Purinergic P2Y2 | 1 | 2023 | 16 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1387 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 1079 | 0.050 |
Why?
|
| Nucleotides | 1 | 2023 | 89 | 0.050 |
Why?
|
| Energy Intake | 1 | 2025 | 502 | 0.050 |
Why?
|
| Texas | 1 | 2011 | 3624 | 0.050 |
Why?
|
| Adenoviruses, Human | 1 | 2023 | 97 | 0.050 |
Why?
|
| Cytokines | 2 | 2023 | 1344 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 1418 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 161 | 0.050 |
Why?
|
| Hepatic Artery | 1 | 2022 | 45 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2008 | 2562 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 302 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2025 | 494 | 0.040 |
Why?
|
| Catheters | 1 | 2022 | 85 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2011 | 3717 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 336 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 108 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2021 | 118 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2024 | 400 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2023 | 770 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2021 | 104 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2021 | 102 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 4484 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2021 | 6491 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2023 | 582 | 0.040 |
Why?
|
| Graft Survival | 1 | 2022 | 463 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 794 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2026 | 2313 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1317 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2018 | 229 | 0.030 |
Why?
|
| Linear Models | 1 | 2018 | 690 | 0.030 |
Why?
|
| United States | 2 | 2024 | 11852 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1165 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2018 | 558 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 659 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2021 | 951 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2013 | 44 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2013 | 98 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2013 | 110 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 363 | 0.020 |
Why?
|
| Calcium | 1 | 2017 | 1030 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2017 | 1075 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 2212 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2013 | 234 | 0.020 |
Why?
|
| Encephalomyocarditis virus | 1 | 2011 | 6 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 716 | 0.020 |
Why?
|
| Adult | 2 | 2024 | 31296 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2013 | 689 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 784 | 0.020 |
Why?
|
| Viral Load | 1 | 2011 | 403 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 10016 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 1014 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 529 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2851 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1216 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1599 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1852 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 2345 | 0.010 |
Why?
|